Advanced

Cost effectiveness of adding budesonide/formoterol to tiotropium in COPD in four Nordic countries

Nielsen, Rune ; Kankaanranta, Hannu ; Bjermer, Leif LU ; Lange, Peter ; Arnetorp, Sofie ; Hedegaard, Morten ; Stenling, Anna and Mittmann, Nicole (2013) In Respiratory Medicine 107(11). p.1709-1721
Abstract
Objective: Assess the cost effectiveness of budesonide/formoterol (BUD/FORM) Turbuhaler (R) +tiotropium (TIO) HandiHaler (R) vs. placebo (PBO)+TIO in patients with chronic obstructive pulmonary disease (COPD) eligible for inhaled corticosteroids/long-acting beta(2)-agonists (ICS/LABA). Methods: The cost-effectiveness analysis was based on the 12-week, randomised, double-blind CLIMB trial. The study included 659 patients with pre-bronchodilator forced expiratory volume in 1 s <= 50% and >= 1 exacerbation requiring systemic glucocorticosteroids or antibiotics the preceding year. Patients received BUD/FORM 320/9 mu g bid + TIO 18 mu g qd or PBO bid + TIO 18 mu g qd. Effectiveness was defined as the number of severe exacerbations... (More)
Objective: Assess the cost effectiveness of budesonide/formoterol (BUD/FORM) Turbuhaler (R) +tiotropium (TIO) HandiHaler (R) vs. placebo (PBO)+TIO in patients with chronic obstructive pulmonary disease (COPD) eligible for inhaled corticosteroids/long-acting beta(2)-agonists (ICS/LABA). Methods: The cost-effectiveness analysis was based on the 12-week, randomised, double-blind CLIMB trial. The study included 659 patients with pre-bronchodilator forced expiratory volume in 1 s <= 50% and >= 1 exacerbation requiring systemic glucocorticosteroids or antibiotics the preceding year. Patients received BUD/FORM 320/9 mu g bid + TIO 18 mu g qd or PBO bid + TIO 18 mu g qd. Effectiveness was defined as the number of severe exacerbations (hospitalisation/emergency room visit/systemic glucocorticosteroids) avoided. A sub-analysis included antibiotics in the definition of an exacerbation. Resource use from CLIMB was combined with Danish (DKK), Finnish (sic), Norwegian (NOK) and Swedish (SEK) unit costs (2010). The incremental cost-effectiveness ratios (ICERs) for BUD/FORM + TIO vs. PBO + TIO were estimated using descriptive statistics and uncertainty around estimates using bootstrapping. Analyses were conducted from the societal and healthcare perspectives in Denmark, Finland, Norway and Sweden. Results: From a societal perspective, the ICER was estimated at (sic)174/severe exacerbation avoided in Finland while BUD/FORM + TIO was dominant in the other countries. From the healthcare perspective, ICERs were DKK 1580 ((sic)212), (sic)307 and SEK 1573 ((sic) 165) per severe exacerbation avoided for Denmark, Finland and Sweden, respectively, while BUD/FORM + TIO was dominant in Norway. Including antibiotics decreased ICERs by 8-15%. Sensitivity analyses showed that results were overall robust. Conclusion: BUD/FORM + TIO represents a clinical and economic benefit to health systems and society for the treatment of COPD in the Nordic countries. (ClinicalTrials.gov Identifier: NCT00496470). (C)2013 Elsevier Ltd. All rights reserved. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
Budesonide/formoterol, Tiotropium, Cost effectiveness, Nordic, COPD
in
Respiratory Medicine
volume
107
issue
11
pages
1709 - 1721
publisher
Elsevier
external identifiers
  • wos:000327230800009
  • scopus:84887099441
  • pmid:23856511
ISSN
1532-3064
DOI
10.1016/j.rmed.2013.06.007
language
English
LU publication?
yes
id
cada15f1-5586-4b89-ab9b-b291d6beee89 (old id 4197790)
date added to LUP
2016-04-01 13:51:27
date last changed
2020-01-12 13:53:20
@article{cada15f1-5586-4b89-ab9b-b291d6beee89,
  abstract     = {Objective: Assess the cost effectiveness of budesonide/formoterol (BUD/FORM) Turbuhaler (R) +tiotropium (TIO) HandiHaler (R) vs. placebo (PBO)+TIO in patients with chronic obstructive pulmonary disease (COPD) eligible for inhaled corticosteroids/long-acting beta(2)-agonists (ICS/LABA). Methods: The cost-effectiveness analysis was based on the 12-week, randomised, double-blind CLIMB trial. The study included 659 patients with pre-bronchodilator forced expiratory volume in 1 s &lt;= 50% and &gt;= 1 exacerbation requiring systemic glucocorticosteroids or antibiotics the preceding year. Patients received BUD/FORM 320/9 mu g bid + TIO 18 mu g qd or PBO bid + TIO 18 mu g qd. Effectiveness was defined as the number of severe exacerbations (hospitalisation/emergency room visit/systemic glucocorticosteroids) avoided. A sub-analysis included antibiotics in the definition of an exacerbation. Resource use from CLIMB was combined with Danish (DKK), Finnish (sic), Norwegian (NOK) and Swedish (SEK) unit costs (2010). The incremental cost-effectiveness ratios (ICERs) for BUD/FORM + TIO vs. PBO + TIO were estimated using descriptive statistics and uncertainty around estimates using bootstrapping. Analyses were conducted from the societal and healthcare perspectives in Denmark, Finland, Norway and Sweden. Results: From a societal perspective, the ICER was estimated at (sic)174/severe exacerbation avoided in Finland while BUD/FORM + TIO was dominant in the other countries. From the healthcare perspective, ICERs were DKK 1580 ((sic)212), (sic)307 and SEK 1573 ((sic) 165) per severe exacerbation avoided for Denmark, Finland and Sweden, respectively, while BUD/FORM + TIO was dominant in Norway. Including antibiotics decreased ICERs by 8-15%. Sensitivity analyses showed that results were overall robust. Conclusion: BUD/FORM + TIO represents a clinical and economic benefit to health systems and society for the treatment of COPD in the Nordic countries. (ClinicalTrials.gov Identifier: NCT00496470). (C)2013 Elsevier Ltd. All rights reserved.},
  author       = {Nielsen, Rune and Kankaanranta, Hannu and Bjermer, Leif and Lange, Peter and Arnetorp, Sofie and Hedegaard, Morten and Stenling, Anna and Mittmann, Nicole},
  issn         = {1532-3064},
  language     = {eng},
  number       = {11},
  pages        = {1709--1721},
  publisher    = {Elsevier},
  series       = {Respiratory Medicine},
  title        = {Cost effectiveness of adding budesonide/formoterol to tiotropium in COPD in four Nordic countries},
  url          = {http://dx.doi.org/10.1016/j.rmed.2013.06.007},
  doi          = {10.1016/j.rmed.2013.06.007},
  volume       = {107},
  year         = {2013},
}